

**Session Title:** #235: Sex and the Survivor

**Session Type:** Extended Education Session

**Date:** Friday, June 4

**Location:** E Arie Crown Theater

**Time:** 1:00 PM - 3:15 PM

- Overview of Current Strategies to Prevent and Treat Cancer-Related Sexual Dysfunction

*Leslie R. Schover, PhD*

- Preventing and Treating Sexual Dysfunction in Women with Breast Cancer

*Patricia A. Ganz, MD*

- Gynecologic Approach to Women's Cancer-Related Sexual Dysfunction

*Stacy Tessler Lindau, MD, MAPP*

- Urologic Treatment of Men's Cancer-Related Sexual Dysfunction

*John Mulhall, MD*

- Sexuality in survivors of colorectal cancer

*Francesco Di Fabio, MD*

- SPIRIT: Peer Counseling to Promote Reproductive Health in African-American Breast Cancer Survivors

*Michelle Marion Rhodes, PhD*

- Sexual Impact of Being at High Genetic Risk for Cancer

*Sharon L. Bober, PhD*

---

**Session Title:** #52: Future Treatment Approaches toward Colorectal Cancer: New Therapeutic Pathways, New Targets

**Session Type:** Education Session

**Date:** Friday, June 4

**Location:** E Hall D1

**Time:** 2:45 PM - 4:00 PM

- Membrane receptors as targets for therapeutic approaches in colorectal cancer

*Josep Taberero, MD*

- Intracellular components of signal transduction pathways as therapeutic targets in colorectal cancer

*Wells A. Messersmith, MD*

- Small and large-molecule angiogenesis inhibitors - excitement and disappointments

*Scott Kopetz, MD*

---

**Session Title:** #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

**Session Type:** Special Session

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

*Daniel D. Von Hoff, MD*

---

**Session Title:** #68: Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions)

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E354b

**Time:** 1:15 PM - 2:30 PM

- Managing and reducing side effects of pelvic radiation

*Bruce D. Minsky, MD*

- Dermatologic toxicities of targeted therapy in colorectal cancer

*Mario E. Lacouture, MD*

- Management of oxaliplatin-induced neurotoxicity

*Howard S. Hochster, MD*

**Session Title:** #112: Clinical Management of Hereditary Colorectal Cancer

**Session Type:** Meet the Professor Session

**Date:** Saturday, June 5

**Location:** E451b

**Time:** 3:00 PM - 4:15 PM

- Clinical Management of Hereditary Colorectal Cancer

*Randall Burt, MD*

**Session Title:** #167: Highlights of the Day I including Clinical Trials Participation Awards

**Session Type:** Highlights of the Day

**Date:** Sunday, June 6

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

*Everett E. Vokes, MD*

- Clinical Trials Participation Awards

*Douglas W. Blayney, MD*

- Discussion: Lymphoma and Plasma Cell Disorders

*Bruce D. Cheson, MD*

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

*Alan B Sandler, MD*

- Discussion: Patient and Survivor Care

*Gretchen Genevieve Kimmick, MD*

- Discussion: Melanoma/Skin Cancers

*F. Stephen Hodi, MD*

**Session Title:** #30: Controversies in the Management of Colorectal Cancer

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** N Hall B1

**Time:** 8:00 AM - 9:15 AM

- Is there an optimal treatment strategy for advanced colorectal cancer?

- Treatment of colorectal cancer with peritoneal carcinomatosis - knife, drugs, or both?

*David L. Bartlett, MD*

- Neoadjuvant therapy of rectal cancer - how can we make it better?

*Claus Roedel, MD*

---

**Session Title:** #150: Gastrointestinal (Colorectal) Cancer

**Session Type:** Oral Abstract Session

**Date:** Sunday, June 6

**Location:** E Hall D1

**Time:** 9:30 AM - 12:30 PM

- Gastrointestinal (Colorectal) Cancer

*Chris R. Garrett, MD*

- Gastrointestinal (Colorectal) Cancer

*Tanios S. Bekaii-Saab, MD*

- #3501-Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]).

*Josep Tabernero, MD*

- #3502-Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial.

*Timothy Stanley Maughan*

- #3526-Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM).

*Theo Ruers*

- Discussion

*Alan Paul Venook, MD*

- #3503-Comparison of molecular and pathologic features of stage II and stage III colon cancer in 4 large studies conducted for development of the 12-gene colon cancer recurrence score.

*Michael J. O'Connell*

- #3504-Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC): Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial.

*Arnaud Roth*

- #3505-Mutant KRAS and BRAF gene expression profiles in colorectal cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial.

*Sabine Tejpar, MD, PhD*

- #3506-Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status.

*Carsten Bokemeyer*

- Discussion

*Charles Fuchs, MD*

- #CRA3507-Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147.

*Steven R. Alberts*

- #3508-Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup phase III trial N0147.

*Richard M. Goldberg, MD*

- Discussion

*Louis M. Weiner, MD*

**Session Title:** #8: Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** S100a

**Time:** 9:45 AM - 11:00 AM

- Benefits of Adjuvant Therapy

*Peter Ravdin, MD*

- Estimating life expectancy and benefit from adjuvant therapy based on comorbidity

*Supriya Gupta Mohile, MD, MS*

- The Importance of Shared Decision-Making Regarding Adjuvant Therapy

*Arash Naeim, MD*

**Session Title:** #132: Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors: What to Do after Adjuvant Therapy?

**Session Type:** Clinical Problems in Oncology Session

**Date:** Sunday, June 6

**Location:** E451a

**Time:** 11:30 AM - 12:45 PM

- Pharmacologic interventions to lower the risk of tumor recurrence in patients with resected colorectal cancer

*David P. Ryan, MD*

- Beyond standard surgery and chemotherapy to lower the risk of tumor recurrence in patients with resected colorectal cancer

*Jeffrey A. Meyerhardt, MD, MPH*

**Session Title:** #143: Plenary Session including Science of Oncology Award and Lecture

**Session Type:** Plenary Session

**Date:** Sunday, June 6

**Location:** N Hall B1

**Time:** 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture

*Douglas W. Blayney, MD*

- Plenary Session including Science of Oncology Award and Lecture

*Daniel F. Hayes, MD*

- Plenary Session including Science of Oncology Award and Lecture

*Frank McCormick, PhD, FRS*

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

*Robert A Burger*

- Discussion

*Elizabeth A. Eisenhauer, MD*

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

*Elisabeth A. Quoix*

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

*Steven O'Day, MD*

- Discussion: Ipilimumab: The light at the end of the tunnel?

*Vernon K Sondak, MD*

---

**Session Title:** #199: Gastrointestinal (Colorectal) Cancer

**Session Type:** General Poster Session

**Date:** Sunday, June 6

**Location:** S Hall A2

**Time:** 2:00 PM - 6:00 PM

1A #3534-PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.

*Scott Kopetz, MD*

1C #3536-Phase IB study of the src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer.

*Christopher Hanyoung Lieu*

1D #3537-Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC).

*Michael B. Sawyer*

1E #3538-Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).

*Niall Christopher Tebbutt*

1F #3539-Phase II study of bevacizumab (B) plus oxaliplatin (Ox) plus capecitabine (C) followed by bevacizumab (B) plus erlotinib (E) as first-line treatment in metastatic colorectal cancer (mCRC).

*Alberto Muñoz*

1G #3540-Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).

*Nicolas Moosmann*

1H #3541-Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG).

*Dimitrios G. Pectasides*

2A #3542-CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC).

*Nikolaos Ziras*

2B #3543-FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO).

*Alfredo Falcone*

2C #3544-Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983).

*Halfdan Sorbye*

2D #3545-Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Resections and curative surgery in a phase II single arm, multicenter study (20060314).

*Ralf Hofheinz*

2E #3546-Surgical cytoreduction in patients with colorectal peritoneal carcinomatosis treated with contemporary chemotherapy.

*Vinicius G Gava*

2F #3547-Outcome of 123 patients (pts) with peritoneal carcinomatosis (PC) and limited metastases from colorectal cancer (CRC) and appendiceal adenocarcinoma (ADC): The British Columbia Cancer Agency (BCCA) experience.

*Francine Aubin*

2G #3548-Outcome of colorectal liver metastases vanishing under chemotherapy and finally missing after surgery.

*Sebastien Gaujoux*

2H #3549-Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C.

*Axel Grothey, MD*

3A #3550-FEB study: Efficacy treatment evaluation in metastatic colorectal cancer (mCRC) patients (pts) changing monoclonal antibody (MA) after progression with chemotherapy.

*Roberta Grande*

3B #3551-CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) plus cetuximab (Cmab) in unselected advanced colorectal cancer (ACC) patients.

*Carlo Garufi*

3C #3552-Metronomic therapy irinotecan (IRI) capecitabine (CAP) plus bevacizumab (BEV) in treatment of advanced colorectal cancer (ACRC) in very elderly people.

*Ignazio Ugo Carreca*

3D #3553-Phase II trial alternating mFOLFOX 6 and FOLFIRI (FIREFOX) regimens in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0701).

*Yoshito Akagi*

3E #3554-Analysis of prognostic factors for 60-day mortality: Evaluation of a randomized phase III trial investigating FUFIRI versus mIROX as first-line treatment of metastatic colorectal cancer (mCRC).

*Clemens Giessen*

3F #3555-Capecitabine (C) and bevacizumab (B) for nonresectable metastatic colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial.

*Albrecht Kretschmar*

3G #3556-Incidence and risk factors for biliary sclerosis following adjuvant hepatic arterial infusion with floxuridine after hepatectomy for metastatic colorectal cancer.

*Kaori Ito*

3H #3557-A randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.

*Nancy E. Kemeny*

4A #3558-Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE): A multicenter phase II study.

*David Malka*

4B #3559-Unexpected increased biliary toxicity when systemic bevacizumab is added to hepatic arterial infusion.

*Derek Gerard Power, Bsc, MD*

4C #3560-Feasibility of neoadjuvant transarterial chemoembolization (TACE) using irinotecan beads (DEBIRI) before hepatectomy (HPX) for easily resectable colorectal liver metastases (RCLM): A phase II study.

*Graeme John Poston*

4D #3561-Premedication and incidence of infusion-related reactions in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan-based chemotherapy.

*Hansjochen Wilke*

4E #3562-Use of germ-line polymorphisms in genes involved in the IGF pathway to predict efficacy of cetuximab independent of K-ras in mCRC patients (IMCL-0144).

*Thomas Winder*

4F #3563-Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in advanced rectal cancer.

*Daniel Vallbohmer*

4G #3564-Early magnesium modifications as a surrogate markers of efficacy of cetuximab based anticancer treatment in kras wild-type colorectal cancer patients.

*Bruno Vincenzi*

4H #3565^-Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining.

*Marc Peeters*

5A #3566^-Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining.

*Salvatore Siena*

5B #3567-Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC).

*Arjun Sood*

5C #3568-Relationship between K-Ras mutational status and EGFR expression evaluated using Allred score in primary and metastatic colorectal cancer.

*Elisa Melucci*

5D #3569-Economic impact in the management of dermatologic toxicities (dT<sub>s</sub>) induced by the epidermal growth factor receptor inhibitor (EGFRI) cetuximab in colorectal cancer.

*Judy H Borovicka, MD*

5E #3570-Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of *KRAS* and *BRAF* biomarker status with treatment outcome.

*Eric Van Cutsem*

5F #3571-Impact of the amount of tumor cells in tissue samples for detection of *KRAS* mutations in colorectal cancer.

*Janick Selves*

5G #3572-KRAS mutation testing in patients with metastatic colorectal carcinoma: An 18-month experience emphasizing the risk of false-negative results.

*Frédéric Bibeau*

5H #3573-Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy.

*Benny Vittrup Jensen*

6A #3574-Predictive role of carcinoembryonic antigen (CEA) for therapeutic efficacy of angiogenesis-targeting therapy in colorectal cancer: Novel clinical observation based upon recently discovered CEA biology.

*Kira H. Bramswig*

6B #3575-Bevacizumab-induced changes in small arterial dilatation measured in vivo by dynamic retinal vessel analysis.

*Gunnar Folprecht*

6C #3576-Gene expression profiles to predict outcome following liver resection in patients with metastasis of colorectal cancer.

*Hironichi Ito*

6D #3577-Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer.

*Benoist Chibaudel, MD*

6E #3578-Selecting colorectal cancer (CRC) patients for therapy based on mutational analysis by next generation sequencing: Are we analyzing the appropriate tumor?

*Joost S Vermaat*

6F #3579-Association between deficient mismatch repair system and efficacy to irinotecan containing first-line chemotherapy in patients with sporadic metastatic colorectal cancer.

*Jeong-Eun Kim*

6G #3580-Detector-c: A blood-based IVD with high sensitivity and specificity for early detection of colorectal cancer.

*André Rosenthal*

6H #3581-Correlation between bevacizumab-related hypertension and response in mCRC patients.

*Alfonso De Stefano, MD*

7A #3582-Personalized adjuvant chemotherapy for colorectal cancer based on an individual 50% inhibitory area under the concentration curve using collagen gel droplet embedded culture-drug sensitivity test.

*Takumi Ochiai*

7B #3583-Genetic polymorphism associated with chronic neurotoxicity and recurrence in curatively-resected colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.

*Soo-Youn Lee*

7C #3584-Are MGMT promoter methylation and EGFR mutations early markers of tumor progression in colorectal cancer?

*Thomas Wenner*

7D #3585-Prospective study of paresthetic neurotoxicity from oxaliplatin-based regimens in the treatment of colorectal cancer.

*Xin Shelley Wang*

7E #3586-Prognostic values of micrnas in patients with Dukes's B and C colon cancer.

*Mihriban Karaayvaz*

7F #3587-Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting.

*Angelos Koutras*

7G #3588-New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC).

*Eva Budinska*

7H #3589-Analysis of EGFR pathway mediators in KRAS wild-type primary tumors is not representative of their status in related metastases.

*Paloma Cejas*

8A #3590-Association of GRP78 polymorphisms with response and TTP in patients with mCRC treated with FOLFOX/BV or XELOX/BV.

*Heinz-Josef Lenz, MD*

8B #3591-Lessons from PETACC 2: No prognostic impact of KRAS-/BRAF-status in stage III colon cancer treated with adjuvant 5-FU monotherapy.

*Daniela Ellen Aust, MD*

8C #3592-Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers.

*Ben Tran*

8D #3593-Number of lymph nodes examined and prognosis among pathologically node-negative patients after preoperative chemoradiation for rectal cancer.

*C Jillian Tsai, MD, PhD*

8E #3594-Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study.

*Eric Terrebonne*

8F #3595-Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).

*Tanios S. Bekaii-Saab, MD*

8G #3596-Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).

*Allen Lee Cohn*

8H #3597-Molecular classes in CRC: Characterization of MSI by expression profiling in the translational study of the PETACC 3-EORTC 40993-SAKK 60-00 trial.

*Mauro Delorenzi, PhD*

9A #3598-Impact of ethnicity and insurance on colorectal cancer outcomes.

*Kristal B. Young*

9B #3599-Use of day 4 CEP and baseline CXCR4 plus CEC as predictive markers for bevacizumab in mCRC.

*Satoshi Matsusaka*

9C #3600-Use of a four gene panel of epigenetic markers to classify serrated colonic adenomas with CpG island methylator phenotype.

*Jenia Jenab-Wolcott*

9D #3601-Prognostic factors for actual 5-year survivors after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal surface disease.

*Perry Shen*

9E #3602-Global microRNA expression and survival in patients with metastatic colorectal cancer in third-line treatment with cetuximab and irinotecan.

*Jakob Vasehus Schou*

9F #3603-Incidence of diagnosed VTE among elderly Americans in the year following stage III or IV colon cancer diagnosis.

*C. Daniel Mullins*

9G #3604-Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of over 6,000 patients in randomized phase II and III studies.

*James Cassidy*

9H #3605-Adjuvant chemotherapy for colorectal cancer in the over 75 age group: A 10-year experience.

*Richard M Bambury, MD*

10A #3606-Predictors of lymph node count in colon adenocarcinoma.

*Kellie Leanne Mathis*

10B #3607-The number of lymph nodes is influenced by the MSI phenotype in resected colorectal cancers (CRC): A study in a large monocentric series.

*Jean-François Flejou*

10C #3608-Clinicopathologic factors and outcomes associated with lymph node retrieval in resectable colon cancer.

*Swapna Kanuri*

10D #3609-Clinicopathologic significance of p53, hypoxia-inducible factor 1 alfa, and vascular endothelial growth factor expression in colorectal cancer.

*Hyuk-Chan Kwon*

10E #3610-Mutation-based detection of molecular tumor margins in colorectal liver metastasis.

*Kerstin Schmidt*

10F #3611-Safety analysis of FOLFOX4 treatment in advanced/recurrent or adjuvant colorectal cancer in Asian and western patients.

*Kenichi Sugihara*

10G #3612-Predictor c: A tissue-based IVD predicting progression of disease in colorectal cancer UICC stages II or III.

*André Rosenthal*

10H #3613-Oxaliplatin- or irinotecan-based combination therapy versus 5-fluorouracil/leucovorin alone in the treatment of advanced colon cancer patients age 66 and older: An analysis using SEER-Medicare data.

*Fei-Yuan Sharon Hsiao*

11A #3614-Analysis of KRAS mutations in colorectal cancer (CRC) patients by gender in a Brazilian cohort of 3,346 patients.

*Carlos G. M. Ferreira*

11B #3615-Vitamin D levels and survival in colorectal cancer (CRC).

*Kathleen Mary Wesa*

11F #3616-Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS)-Findings from the ACCENT dataset.

*Thierry Andre*

11G #3617-Genetic polymorphism and toxicity of adjuvant FOLFOX-4 chemotherapy in Korean colon cancer patients.

*Hye Jung Chang*

11H #3618-Reproductive history and risk of colorectal cancer in postmenopausal women.

*Alice Zervoudakis*

12A #3619-The effect of opposed versus unopposed hormone replacement therapy (HRT) on the risk of colorectal cancer (CRC).

*Kueiyu Lin*

12B #3620-Guideline adherence rates of chemotherapy treatment for colon cancer patients treated in U.S. community oncology practices.

*Zhaohui Wang*

12F #3621-Presurgical diagnostic accuracy of five imaging procedures in chemotherapy-naïve (group A) or chemotherapy-pretreated (group B) patients with colorectal liver metastases (Italian PROMETEO Study).

*Fabiola Lorena Rojas Llimpe*

12G #3622-Dietary grape-derived resveratrol for colon cancer prevention.

*Micaela Martinez*

12H #3623-Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer.

*Diego Villa, MD, MPH*

13A #3624-Association of survival outcomes with dose intensity of adjuvant therapy (AT) with capecitabine for colorectal cancer (CRC).

*Jeremy Ho*

13B #3625-Characterize medical care during disease phases in metastatic colorectal cancer.

*Xue Song*

13C #3626-Use of an electronic health record (iKnowMed), in conjunction with evidence-based pathways, for data capture and outcome measurement in colorectal cancer patients treated with first-line therapy in the US Oncology Network.

*Thomas H. Cartwright*

13D #3627-Spectrum of colon polyposis and colonic neoplasia in the PTEN hamartoma tumor syndrome (PHTS).

*Peter P. Stanich*

13E #3628-Treatment patterns in patients with colorectal liver metastasis: A cohort study.

*Daniel A. Anaya*

13F #3629-The awareness and knowledge levels of colorectal cancer (CRC) patients and their first-degree relatives (FDR) for CRC screening.

*Cagatay Arslan*

13G #3630-To detect Lynch syndrome patients, which colorectal cancers should be tested for microsatellite instability?

*Bruce M. Boman*

13H #3631-A novel, noninvasive, mRNA gene expression colon cancer screening methodology.

*Lisa A Boardman, MD*

14A #3632-Results of a German noninterventional study (NIS) of cetuximab-based therapy in pretreated patients (pts) with metastatic colorectal cancer (mCRC).

*Christian Jehn*

14B #3633-Timing of failure of resected rectal cancer: What is the appropriate duration of postoperative imaging?

*Katherine Fischkoff*

14C #3634-Preoperative chemoradiotherapy (QRTP) and total mesorectal excision (TME) by laparoscopy (LPS) in rectal cancer (RC): Long-term outcomes.

*Estela Pineda*

14D #3635-A randomized phase II trial of preoperative chemoradiotherapy with or without cetuximab in locally advanced adenocarcinoma of the rectum.

*A. David McCollum*

14E #3636-Preoperative chemoradiation (CRT) with concurrent capecitabine and irinotecan in MRI-defined locally advanced rectal cancer: Relationship of histologic downstaging to long-term survival end points.

*Simon William Gollins*

14F #3637-Chemotherapy induction followed by preoperative chemoradiation versus preoperative chemoradiation alone in locally advanced rectal cancer (LARC): A randomized controlled phase II study.

*Raphaël Maréchal*

14G #3638-Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer: A phase II multicenter study of the Dutch Colorectal Cancer Group.

*Tonnis H. van Dijk*

14H #3639-Effect of preoperative radiotherapy on local recurrences in rectal cancer patients with *PIK3CA* mutation.

*Youji He*

15A #3640-Association of intratumoral gene expression levels of thymidine phosphorylase (TP) and VEGF with clinical outcome in stage II/III rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (SWOG 9304).

*Robert D. Ladner*

15B #3641-Use of EGF a+61G and TS-5'UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery.

*Siwen Hu-Lieskovan*

15C #3642-Predictors of site-specific recurrence following combined modality therapy for locally advanced rectal cancer.

*Pei-Rong Ding*

15D #3643-Single nucleotide polymorphisms (SNPs) of hypoxia-related genes correlate with pathologic complete response (pCR) following neoadjuvant chemoradiation (chemoXRT) for locally advanced rectal cancer.

*Motofumi Tanaka*

15E #3644-Patterns of recurrence in rectal cancer treated with neoadjuvant chemoradiotherapy and TME.

*David Liska*

15G #3646-Local excision after neoadjuvant chemoradiation for rectal cancer: Is it an acceptable treatment option?

*Baruch Brenner*

15H #3647-Multimodal salvage therapy for locally recurrent and re-recurrent rectal cancer.

*Y. Nancy You, MD, MHS*

16A #3648-Plasma levels of total RNA and hTERT mRNA as biomarkers of response in rectal cancer patients receiving preoperative chemoradiotherapy.

*Salvatore Pucciarelli*

16B #3649-Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation.

*Andrea Cercek*

16C #3650-KRAS mutation status and clinical outcome of preoperative chemoradiation (CRT) with or without cetuximab in locally advanced rectal cancer (LARC): A pooled analysis of two phase II trials.

*Sun Young Kim*

16D #3651-Quantitative assessment of tumor cell density in rectal cancer following three different preoperative therapies compared to surgery alone.

*Nicholas P West, MB, ChB, BSc*

16E #3652-Relationship of completion of planned treatment and timing of adjuvant chemotherapy to survival in patients with colorectal cancer (CRC).

*Shahid Ahmed*

16F #3653-EGFR, PTEN, and survivin expression in pre- and posttherapeutic specimens does not predict a clinical benefit from preoperative chemoradiation with cetuximab in patients (pts) with locally advanced rectal cancer (LARC).

*Kathrin Dellas*

16G #3654-Evaluation of serum/plasma VEGF/e-selectin and 18F-FDG PET uptake after panitumumab infusion in locally advanced rectal cancer (LARC) patients treated with chemoradiation (CTRT) (StarPan/STAR-02 phase II study).

*Sara Pini*

16H #3655-Treatment of rectal carcinoid tumors and role of preoperative imaging.

*Takayuki Akasu*

17A #3656-Do older Americans undergo stoma reversal following low anterior resection for rectal cancer?

*Christopher M. Dodgion*

17B #3657-Bowel dysfunction after sphincter-preserving surgery.

*Larissa K. F. Temple*

17C #3658-The prognostic significance of tumor human papillomavirus status in patients with anal squamous cell carcinoma treated with combined chemoradiotherapy.

*Ho-Young Yhim*

---

**Session Title:** #10: Aging, Frailty, and Medical Therapy for Colorectal Cancer: Who Should Be Treated and How?

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** S404

**Time:** 4:45 PM - 6:00 PM

- Age and frailty - more than two sides of the same coin?

*Martine Extermann, MD*

- Age, frailty, and chemotherapy - data, more data, and more confusion

*Daniel J. Sargent, PhD*

- Elderly and/ or frail patients with colorectal cancer - a clinician's approach

*Richard M. Goldberg, MD*

---

**Session Title:** #88: Physical Activity in Cancer Populations: What's New?

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** E354b

**Time:** 4:45 PM - 6:00 PM

- Physical Activity and Cancer: Overview and Implications for Survivorship

*Jennifer A. Ligibel, MD*

- Randomized trials of exercise in cancer patients: Health-related fitness and patient-reported outcomes

*Kerry S. Courneya, PhD*

- Exercise Testing and Prescription for Cancer Survivors: Guidelines from the American College of Sports Medicine

*Kathryn Schmitz, PhD, MPH*

---

**Session Title:** #168: Highlights of the Day II including Partners in Progress Award

**Session Type:** Highlights of the Day

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

*Kim Allyson Margolin, MD*

- Highlights of the Day II including Partners in Progress Award

*Douglas W. Blayney, MD*

- Partners in Progress Award Recipient

*Ellen V. Sigal, PhD*

- Discussion: Genitourinary (Prostate) Cancer  
*Nicholas J. Vogelzang, MD*
  - Discussion: Gastrointestinal (Colorectal) Cancer  
*Howard S. Hochster, MD*
  - Discussion: Gynecologic Cancer  
*Claire F. Verschraegen, MD*
  - Discussion: Myeloma  
*Jean L. Harousseau, MD*
  - Discussion: Cancer Prevention/Epidemiology  
*Scott Michael Lippman, MD*
- 

**Session Title:** #16: Biomarker-driven Treatment in Stage II Colon Cancer: When to Hold and When to Fold

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S100a

**Time:** 8:00 AM - 9:15 AM

- Overview of adjuvant clinical trials in stage II colon cancer - results, challenges, and confusion  
*Al Bowen Benson, III, MD*
  - Prognostic and predictive molecular biomarkers in stage II colon cancer - current evidence and future perspective  
*Sabine Tejpar, MD, PhD*
  - Biomarker-driven treatment decisions in stage II colon cancer - making sense of what we know  
*Neal J. Meropol, MD*
- 

**Session Title:** #169: Highlights of the Day III

**Session Type:** Highlights of the Day

**Date:** Tuesday, June 8

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day III  
*Kathy Miller, MD*

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy  
*Kathy Miller, MD*
  - Discussion: Lung Cancer - Metastatic  
*Charles M. Rudin, MD, PhD*
  - Discussion: Sarcoma  
*Gary K. Schwartz, MD*
  - Discussion: Gastrointestinal (Noncolorectal) Cancer  
*C. D. Blanke, MD*
  - Discussion: Head and Neck Cancer  
*Everett E. Vokes, MD*
- 

**Session Title:** #177: Gastrointestinal (Colorectal) Cancer

**Session Type:** Poster Discussion Session

**Date:** Tuesday, June 8

**Location:** S403

**Time:** 8:00 AM - 12:00 PM

- Gastrointestinal (Colorectal) Cancer  
*Richard Herrmann, MD*
- Gastrointestinal (Colorectal) Cancer  
*John S. Kauh, MD*

1 #3509-A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS).

*Sam Ngan*

2 #3510-Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2uN0 rectal cancer (RC) treated by local excision (LE): Results of the ACOSOG Z6041 trial.

*Julio Garcia-Aguilar*

3 #3511-Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer.

*Deborah Schrag, MD*

4 #3512-Identification of localized rectal cancer (RC) patients (pts) who may not require preoperative (preop) chemoradiation (CRT).

*Desamparados Roda*

- Discussion

*Bruce D. Minsky, MD*

5 #3513-Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients .

*Robert Rosenberg*

6 #3514-Genome-wide association study for germline prognostic markers in colorectal cancer.

*Axel Walther*

7 #3515-Metachronous colorectal cancer in mismatch repair gene mutation carriers: The advantage of more extensive surgery.

*Susan Parry*

8 #3516-Use of a combination of prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy.

*K. L. Pogue-Geile*

9 #3517-Value of mismatch repair, *KRAS*, and *BRAF* mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

*Gordon Hutchins*

10 #3518-Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC).

*George P. Kim*

11 #3519-DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials.

*Frank Sinicrope, MD*

- Discussion

*Patrick Johnston, MD, PhD*

12 #3520-Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials.

*C. D. Blanke, MD*

13 #3521-Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS).

*Daniel G. Haller*

14 #3522-FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial.

*Christophe Tournigand*

15 #3523-Benefits and adverse events (AEs) in younger (Y) (age <50) versus older patients (pts) receiving adjuvant chemotherapy (AT) for colon cancer (CC): Findings from the 33,574 pt ACCENT dataset.

*Daniel J. Sargent, PhD*

16 #3524-Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors.

*Luis Teixeira*

17 #3525-Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial.

*Richard A Adams, BMBS*

18 #3527-A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10.

*Laurence E. McCahill*

19 #3528^--Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

*Jean-Yves Douillard*

20 #3529^--Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

*Timothy Jay Price*

21 #3530-Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).

*Johanna C. Bendell, MD*

22 #3531-Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

*Donald Anthony Richards*

23 #3532-A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results.

*J. Randolph Hecht*

24 #3533-DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.

*Andrew James Weickhardt*

25 #3535-Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).

*Ivy Altomare*

- Discussion

*Wells A. Messersmith, MD*

---

**Session Title:** #138: The Best Treatment for Hepatic Metastases: What Is the Evidence?

**Session Type:** Clinical Problems in Oncology Session

**Date:** Tuesday, June 8

**Location:** E451a

**Time:** 9:45 AM - 11:00 AM

- Review the data supporting chemotherapy and molecular targeted therapy in management of hepatic metastases.

*Heinz-Josef Lenz, MD*

- Evidence for patient benefit using surgical and/or ablation for hepatic metastases.

*Bryan M. Clary, MD*

- The incorporation of conventional and stereotactic body radiation therapy into the treatment of hepatic metastases.

*Christopher Willett, MD*

---

**Session Title:** #244: Gastrointestinal (Colorectal) Cancer

**Session Type:** Poster Discussion Session

**Date:** Tuesday, June 8

**Location:** S406 (Vista Room)

**Time:** 11:00 AM - 12:00 PM

- Gastrointestinal (Colorectal) Cancer

*Richard Herrmann, MD*

- Gastrointestinal (Colorectal) Cancer

*John S. Kauh, MD*

1 #3509-A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS).

*Sam Ngan*

2 #3510-Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2uN0 rectal cancer (RC) treated by local excision (LE): Results of the ACOSOG Z6041 trial.

*Julio Garcia-Aguilar*

3 #3511-Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer.

*Deborah Schrag, MD*

4 #3512-Identification of localized rectal cancer (RC) patients (pts) who may not require preoperative (preop) chemoradiation (CRT).

*Desamparados Roda*

- Discussion

*Bruce D. Minsky, MD*

5 #3513-Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients .

*Robert Rosenberg*

6 #3514-Genome-wide association study for germline prognostic markers in colorectal cancer.

*Axel Walther*

7 #3515-Metachronous colorectal cancer in mismatch repair gene mutation carriers: The advantage of more extensive surgery.

*Susan Parry*

8 #3516-Use of a combination of prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy.

*K. L Pogue-Geile*

9 #3517-Value of mismatch repair, *KRAS*, and *BRAF* mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

*Gordon Hutchins*

10 #3518-Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC).

*George P. Kim*

11 #3519-DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials.

*Frank Sinicrope, MD*

- Discussion

*Patrick Johnston, MD, PhD*

12 #3520-Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials.

*C. D. Blanke, MD*

13 #3521-Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS).

*Daniel G. Haller*

14 #3522-FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial.

*Christophe Tournigand*

15 #3523-Benefits and adverse events (AEs) in younger (Y) (age <50) versus older patients (pts) receiving adjuvant chemotherapy (AT) for colon cancer (CC): Findings from the 33,574 pt ACCENT dataset.

*Daniel J. Sargent, PhD*

16 #3524-Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors.

*Luis Teixeira*

17 #3525-Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial.

*Richard A Adams, BMBS*

18 #3527-A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10.

*Laurence E. McCahill*

19 #3528^-Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

*Jean-Yves Douillard*

20 #3529^-Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

*Timothy Jay Price*

21 #3530-Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).

*Johanna C. Bendell, MD*

22 #3531-Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

*Donald Anthony Richards*

23 #3532-A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results.

*J. Randolph Hecht*

24 #3533-DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.

*Andrew James Weickhardt*

25 #3535-Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).

*Ivy Altomare*

- Discussion

*Wells A. Messersmith, MD*